Original Research Article
A Placebo-Controlled Double-Blind Randomized Study of Venlafaxine in the Treatment of Depression in Dementiade Vasconcelos Cunha U.G.a · Lopes Rocha F.b · Ávila de Melo R.a · Alves Valle E.a · de Souza Neto J.J.a · Mendes Brega R.a · Magalhães Scoralick F.a · Araújo Silva S.a · Martins de Oliveira F.a · da Costa Júnior A.L.a · Xavier Faria Alves V.a · Sakurai E.c
aGeriatric Unit and bPsychiatric Unit, Governador Israel Pinheiro Hospital, and cStatistical Department, Federal University, Minas Gerais, Brazil
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background/Aims: To evaluate the efficacy and safety of venlafaxine in the treatment of major depression in dementia. Methods: Thirty-one outpatients who had dementia and major depression participated in this randomized, double-blind, placebo-controlled, 6-week, flexible dose clinical trial. The screening measures were Cornell Scale for depression in dementia, DSM-IV for depression and dementia and Mini-Mental State Examination. The outcome measures were response rate, Montgomery-Åsberg Depression Rating scale and Clinical Global Impressions. Results: The percentage of patients defined as Montgomery-Åsberg Depression Rating scale responders was approximately the same in the placebo and in the venlafaxine groups. Clinical Global Impressions showed no significant difference between the groups. The reasons for dropouts show borderline significance between the two groups. There was no statistically significant difference in the incidence of adverse events between the venlafaxine and placebo-treated groups. Conclusions: Our data do not support the hypothesis that venlafaxine improves mood in elderly demented patients.
© 2007 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.